title: Treatment of squamous cell esophageal cancer with topotecan: an Eastern Cooperative Oncology Group Study (E2293).
abstract: Seventeen patients with enhanced measurable squamous cell carcinoma of the esophagus were treated with topotecan 1.5 mg/m2 daily for 5 days repeated every 21 days. Toxicity was severe, with 1 death from myelotoxicity and 10 patients with life-threatening myelotoxicity. Severe gastrointestinal toxicity consisting of vomiting was also seen in three patients. No response was seen in any of the patients in the study. Topotecan given in this manner has no activity in squamous cell carcinoma of the esophagus.
authors.affiliation: Interlakes Oncology & Hematology, Rochester, New York 14623, USA.
authors.forename: R F
authors.initials: RF
authors.lastname: Asbury
authors.forename: S
authors.initials: S
authors.lastname: Lipsitz
authors.forename: D
authors.initials: D
authors.lastname: Graham
authors.forename: C I
authors.initials: CI
authors.lastname: Falkson
authors.forename: L
authors.initials: L
authors.lastname: Baez
authors.forename: A B
authors.initials: AB
authors.lastname: Benson
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D004938:Esophageal Neoplasms / Q000188:drug therapy*; D006801:Humans; D019772:Topotecan / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D019772:Topotecan